Edition:
United States

Incyte Corp (INCY.O)

INCY.O on Nasdaq

84.87USD
19 Jun 2019
Change (% chg)

$0.59 (+0.70%)
Prev Close
$84.28
Open
$84.71
Day's High
$85.36
Day's Low
$83.70
Volume
1,236,307
Avg. Vol
1,304,523
52-wk High
$88.83
52-wk Low
$57.00

About

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib). JAKAFI... (more)

Overall

Beta: 0.81
Market Cap(Mil.): $24,161.52
Shares Outstanding(Mil.): 210.65
Dividend: --
Yield (%): --

Financials

  INCY.O Industry Sector
P/E (TTM): -- 69.30 32.55
EPS (TTM): -0.78 -- --
ROI: -11.99 8.90 13.82
ROE: -23.24 10.04 15.24

BRIEF-FDA Approves Jakafi For The Treatment Of Patients With Acute Graft-Versus-Host Disease

* FDA APPROVES JAKAFI® (RUXOLITINIB) FOR THE TREATMENT OF PATIENTS WITH ACUTE GRAFT-VERSUS-HOST DISEASE

May 24 2019

Incyte's Jakafi gets FDA approval to treat Graft vs Host Disease

The U.S. Food and Drug Administration on Friday approved Incyte Corp's treatment for acute Graft versus Host disease (GvHD), an inflammatory response by the immune system after a bone marrow transplant.

May 24 2019

UPDATE 1-Incyte's Jakafi gets FDA approval to treat Graft vs Host Disease

May 24 The U.S. Food and Drug Administration on Friday approved Incyte Corp's treatment for acute Graft versus Host disease (GvHD), an inflammatory response by the immune system after a bone marrow transplant.

May 24 2019

Incyte's Jakafi wins FDA nod to treat complication of stem cell transplant

May 24 The U.S. Food and Drug Administration on Friday approved Incyte Corp's treatment for acute graft-versus-host disease, a complication from stem cell transplant.

May 24 2019

Earnings vs. Estimates